Cited by 167Neuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration MechanismsAdenosine and Purinergic Signaling

Calcium signaling and gliotransmission in normal vs. reactive astrocytes

Open access
Agulhon, Cendra, Sun, Min-Yu, Murphy, Thomas, Myers, Timothy, Lauderdale, Kelli, Fiacco, Todd A.·2012·Frontiers in Pharmacology

Abstract

A prominent area of neuroscience research over the past 20 years has been the acute modulation of neuronal synaptic activity by Ca(2+)-dependent release of the transmitters ATP, D-serine, and glutamate (called gliotransmitters) by astrocytes. Although the physiological relevance of this mechanism is under debate, emerging evidence suggests that there are critical factors in addition to Ca(2+) that are required for gliotransmitters to be released from astrocytes. Interestingly, these factors include activated microglia and the proinflammatory cytokine Tumor Necrosis Factor α (TNFα), chemotactic cytokine Stromal cell-Derived Factor-1α (SDF-1α), and inflammatory mediator prostaglandin E2 (PGE(2)). Of note, microglial activation and release of inflammatory molecules from activated microglia and reactive astrocytes can occur within minutes of a triggering stimulus. Therefore, activation of astrocytes by inflammatory molecules combined with Ca(2+) elevations may lead to gliotransmitter release, and be an important step in the early sequence of events contributing to hyperexcitability, excitotoxicity, and neurodegeneration in the damaged or diseased brain. In this review, we will first examine evidence questioning Ca(2+)-dependent gliotransmitter release from astrocytes in healthy brain tissue, followed by a close examination of recent work suggesting that Ca(2+)-dependent gliotransmitter release occurs as an early event in the development of neurological disorders and neuroinflammatory and neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2012.00139

Cites

166 of 171 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Astrocyte immune activation has downstream impacts on cellular glutamate uptake and calcium signaling.

    “Previous work has also highlighted the downstream impacts of astrocyte immune activation on cellular glutamate uptake and calcium signaling (Agulhon et al., 2012; Haroon et al., 2017; Shigetom, et al., 2019; Vallejo-Illarramendi et al., 2006).”

    From Sterol dysregulation in Smith–Lemli–Opitz syndrome causes astrocyte immune reactivity through microglia crosstalk (2022) · cites this paper as Agulhon et al., 2012

    The section on activated microglia and reactive astrocytes describes inflammatory mediators producing astrocytic Ca2+ elevations and glutamate release; the Summary and Perspectives likewise links reactive astrocytes to Ca2+-dependent glutamate release. These passages support the calcium-signaling part, but concern glutamate release, not an effect of immune activation on cellular glutamate uptake. No page number is provided in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Agulhon, C., Sun, M.-Y., Murphy, T., Myers, T., Lauderdale, K., & Fiacco, T. A.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • University of California, Riverside (US)
Corresponding author
Agulhon, Cendra
Venue
Frontiers in Pharmacology
Published
2012
Volume
3
Pages
139-139
ISSN
1663-9812 (ISSN-L)
OpenAlex
W1965276722
Cited by
167
References
167
Citations by year
2026: 5 · 2025: 12 · 2024: 10 · 2023: 14 · 2022: 8 · 2021: 16 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 14 · 2015: 17 · 2014: 16 · 2013: 10 · 2012: 2
FWCI
5.93
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Hellman Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
Keywords
calcium signaling, gliotransmission, reactive astrocytes, ATP release, D-serine, glutamate release, microglial activation, TNF-α, stromal cell-derived factor-1α, prostaglandin E2, neuroinflammation, neurodegeneration, excitotoxicity, hyperexcitability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review